Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012–2018

Supplemental Digital Content is available in the text. Background: Despite the benefits of novel therapeutics, inequitable diffusion of new technologies may generate disparities. We examined the growth of transcatheter aortic valve replacement (TAVR) in the United States to understand the characteristics of hospitals that developed TAVR programs and the socioeconomic status of patients these hospitals served. Methods: We identified fee-for-service Medicare beneficiaries aged 66 years or older who underwent TAVR between January 1, 2012, and December 31, 2018, and hospitals that developed TAVR programs (defined as performing ≥10 TAVRs over the study period). We used linear regression models to compare socioeconomic characteristics of patients treated at hospitals that did and did not establish TAVR programs and described the association between core-based statistical area level markers of socioeconomic status and TAVR rates. Results: Between 2012 and 2018, 583 hospitals developed new TAVR programs, including 572 (98.1%) in metropolitan areas, and 293 (50.3%) in metropolitan areas with preexisting TAVR programs. Compared with hospitals that did not start TAVR programs, hospitals that did start TAVR programs treated fewer patients with dual eligibility for Medicaid (difference of −2.83% [95% CI, −3.78% to −1.89%], P≤0.01), higher median household incomes (difference $2447 [95% CI, $1348–$3547], P=0.03), and from areas with lower distressed communities index scores (difference −4.02 units [95% CI, −5.43 to −2.61], P≤0.01). After adjusting for the age, clinical comorbidities, race and ethnicity and socioeconomic status, areas with TAVR programs had higher rates of TAVR and TAVR rates per 100 000 Medicare beneficiaries were higher in core-based statistical areas with fewer dual eligible patients, higher median income, and lower distressed communities index scores. Conclusions: During the initial growth phase of TAVR programs in the United States, hospitals serving wealthier patients were more likely to start programs. This pattern of growth has led to inequities in the dispersion of TAVR, with lower rates in poorer communities.

[1]  M. Desai,et al.  Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Rheumatic Aortic Stenosis. , 2021, Journal of the American College of Cardiology.

[2]  P. Groeneveld,et al.  The Effects of Market Competition on Cardiologists’ Adoption of Transcatheter Aortic Valve Replacement , 2020, Medical care.

[3]  Kevin L. Thomas,et al.  Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era , 2020, Journal of the American Heart Association.

[4]  C. O'connor,et al.  Transcatheter Aortic Valve Replacement in Low-Population Density Areas , 2020, Circulation. Cardiovascular quality and outcomes.

[5]  M. Hebdon,et al.  Association of Gender and Race With Allocation of Advanced Heart Failure Therapies. , 2020, JAMA network open.

[6]  J. Carroll,et al.  Geographic Access to Transcatheter Aortic Valve Replacement Centers in the United States: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. , 2020, JAMA cardiology.

[7]  M. Mack,et al.  Racial disparities and democratization of health care: A focus on TAVR in the United States. , 2020, American heart journal.

[8]  T. Nazif,et al.  TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making. , 2020, Journal of the American College of Cardiology.

[9]  R. Yeh,et al.  Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. , 2019, Circulation.

[10]  Jane A. Linderbaum,et al.  2019 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: A proposal to optimize care for patients with valvular heart disease: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascula , 2019, The Journal of thoracic and cardiovascular surgery.

[11]  J. Carroll,et al.  Racial Disparities in the Utilization and Outcomes of TAVR: TVT Registry Report. , 2019, JACC. Cardiovascular interventions.

[12]  A. Zaslavsky,et al.  Adjusting for social risk factors impacts performance and penalties in the hospital readmissions reduction program , 2019, Health services research.

[13]  Craig D. Miller,et al.  2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and institutional recommendations and requirements for transcatheter aortic valve replacement: A joint report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiog , 2019, The Journal of thoracic and cardiovascular surgery.

[14]  J. Bavaria,et al.  Cost and contribution margin of transcatheter versus surgical aortic valve replacement , 2017, The Journal of thoracic and cardiovascular surgery.

[15]  M. Mack,et al.  Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER 2 Randomized Clinical Trial , 2017, JAMA cardiology.

[16]  B. Nallamothu,et al.  Geographic access to transcatheter aortic valve replacement relative to other invasive cardiac services: A statewide analysis. , 2016, American heart journal.

[17]  D. Adams,et al.  Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk: Results From the CoreValve US Pivotal Trial. , 2015, JACC. Cardiovascular interventions.

[18]  P. Greenland,et al.  Population-wide trends in aortic stenosis incidence and outcomes. , 2015, Circulation.

[19]  Martin B Leon,et al.  Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). , 2012, Journal of the American College of Cardiology.

[20]  J. Griffith,et al.  A Percutaneous Coronary Intervention Lab in Every Hospital? , 2012, Circulation. Cardiovascular quality and outcomes.

[21]  A. Lleras-Muney,et al.  Technological innovation and inequality in health , 2008, Demography.

[22]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[23]  J. Heikkilä,et al.  Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. , 1993, Journal of the American College of Cardiology.